D
Denteric
Developing vaccines for treating and preventing severe periodontal disease, with the ultimate goal of improving the health of people with this disease
About Denteric
Denteric is a biotechnology startup specializing in oral health, particularly in the development of vaccines to treat and prevent severe periodontal disease. This debilitating gum disease affects one in ten people globally, causing damage to the soft tissue and bone that support the teeth. The company operates in the healthcare and biotechnology market, targeting both individual patients and dental health professionals.
The business model of Denteric revolves around extensive research and development (R&D) to create effective vaccines. By leveraging the expertise of its leadership team, which includes notable figures like Laureate Professor Eric Reynolds AO and Anne Laure, the company aims to bring innovative solutions to market. Professor Reynolds has a distinguished background in dental health, while Anne Laure brings a wealth of experience in immunology and business development.
Denteric makes money primarily through the development and eventual commercialization of its vaccines. This involves securing funding for R&D, conducting clinical trials, and obtaining regulatory approvals. Once the vaccines are approved, the company plans to generate revenue through sales to healthcare providers, dental clinics, and potentially through partnerships with larger pharmaceutical companies.
In summary, Denteric is a cutting-edge biotech firm focused on combating severe periodontal disease through innovative vaccine development, aiming to improve global oral health.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Melbourne, Australia
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 76.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Dentistry, Vaccines, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Sep 2025 | $1.6M | — | CUREator | ↗ |
| GRANTOther financing | Jul 2022 | $0 | — | Brandon Capital Partners · Brandon BioCatalyst | ↗ |
Growth signals
Latest recorded traffic for Denteric is 1.7K monthly website visits, up 0% over the last three months. Denteric's team grew 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Brandon BioCatalyst- CUCUREator
Series A3 investors entered at this stage
Helmedix
CSL
Brandon Capital Partners
Other known investors1 additional known investor
University of Melbourne
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Denteric on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Denteric’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.